HLS Therapeutics Inc.

TSX:HLS Stock Report

Market Cap: CA$154.6m

HLS Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

TSX:HLS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Jun 25BuyCA$3,477Dawn EdinboroIndividual700CA$4.97
31 Dec 24BuyCA$165,783John WelbornIndividual42,184CA$3.93
24 Dec 24BuyCA$1,957Norma BeauchampIndividual500CA$3.91
12 Dec 24BuyCA$6,825John WelbornIndividual2,100CA$3.25
14 Nov 24SellCA$1,655Norma BeauchampIndividual500CA$3.31
14 Aug 24BuyCA$12,741John HannaIndividual4,000CA$3.19

Insider Trading Volume

Insider Buying: HLS insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of HLS?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders216,1490.685%
Institutions3,362,41810.7%
Hedge Funds12,331,92439.1%
General Public15,646,59749.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 17 shareholders own 50.42% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
20.2%
Polar Asset Management Partners Inc.
6,367,082CA$31.2m0%1.38%
18.9%
Stadium Capital Management, LLC
5,964,842CA$29.2m0%14.76%
10.3%
Mawer Investment Management Ltd.
3,237,056CA$15.9m0%0.03%
0.45%
John Welborn
141,284CA$692.3k0%no data
0.2%
Dimensional Fund Advisors LP
63,753CA$312.4k-1.83%no data
0.16%
Jason Gross
49,700CA$243.5k0%no data
0.1%
Rbc Indigo Asset Management Inc
32,529CA$159.4k0%0.01%
0.046%
ATB Investment Management Inc.
14,576CA$71.4k0%no data
0.04%
Craig Millian
12,500CA$61.2k0%no data
0.033%
Highland Capital Management, L.P.
10,445CA$51.2k0%0.01%
0.025%
John Hanna
8,000CA$39.2k0%no data
0.013%
Manulife Asset Management
4,059CA$19.9k0%no data
0.0056%
Kyle Dempsey
1,765CA$8.6k0%no data
0.0038%
Brian Walsh
1,200CA$5.9k0%no data
0.0022%
Dawn Edinboro
700CA$3.4k0%no data
0.0016%
Norma Beauchamp
500CA$2.4k0%no data
0.0016%
Ryan Lennox
500CA$2.4k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/16 18:17
End of Day Share Price 2025/07/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HLS Therapeutics Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity
George UlybyshevClarus Securities Inc.